Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01823978 · ClinicalTrials.gov registry record · Phase 1
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer
A Phase 1 study, sponsored by Bellicum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01823978 is a Phase 1 study that has completed, run by Bellicum Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT01823978, a Phase 1 study, has completed, sponsored by Bellicum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant prostate cancer.
Interventions
- BIOLOGICAL BPX-201 vaccine plus AP1903
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01823978
The ClinicalTrials.gov registry entry for NCT01823978 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellicum Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BPX-201 vaccine plus AP1903 is the first listed.
NCT01823978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01823978 about?
NCT01823978 is a clinical study titled "Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer". This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant prostate cancer.
What is the current status of trial NCT01823978?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-04. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01823978?
The interventions under investigation include: BPX-201 vaccine plus AP1903 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01823978?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.